I like the body language. Much better than Friday afternoon after the market closes.
Closing action today also felt good. Long ways to go however, phew!
Kronos Worldwide, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on March 10, 2016.
Based on representations by Kronos Worldwide, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:
Prices of EpiPens on the rise due to lack of competition, experts say
Channel 3 - WISC-TV3
EpiPen Price Skyrockets, Lack of Competition
Law allows wider access to epinephrine injectors
What's the Story behind Mylan's Revenue Growth?
The growth was driven by increased demand for the EpiPen Auto-injector,
Alabama's new Epi pen law raises questions from child care providers
WRBL Businesses that choose to keep the Epi pens in case of an emergency will have to pay for them and have a prescription.
Market is hot and growing imho. Pressure should be on the FDA to get competition in the market place as in fast track.
Ok I see the reference to NAVB.
But, I'm not seeing anything where he was asked to resign as a result of the accusations you layed out in your original post.
Anton G. Gueth
Mr. Gueth joined the Board of Directors in October 2003 and serves as Chairman of our Compensation Committee and as a member of our Audit Committee and our Governance and Nominating Committee. Since 2003 Mr. Gueth has served as President of Gueth Consulting LLC, which focuses on business development and alliance management in the pharmaceutical industry. He was previously a Managing Director of Burrill Securities, a merchant bank specialized in the health care field, and since 2014 has been serving as Managing Director of EVOLUTION Life Science Partners, an advisory firm specialized on investment banking activities in the healthcare sector. Mr. Gueth was a member of the board of Spectrum Pharmaceuticals, Inc. for the period July 2012 to June 2013. His career includes nearly 19 years with Eli Lilly and Company (“Lilly”), most recently as director of Alliance Management. He also served as General Manager of Lilly’s African and Middle Eastern operations; Vice President of Financial Planning and Treasury of PCS Health Systems; Managing Director of Lilly’s Saudi Arabia, Gulf and Yemen operations, as well as other sales, marketing and financial positions. Mr. Gueth earned a Masters Degree in agricultural economics from the Justus Liebig University in Giessen, Germany, as well as a Masters Degree in public affairs from Indiana University. He is a director of the American Liver Foundation, Northern California Chapter.
I'm not seeing any reference to Navidea. What am I missing.
Your accusation is pretty serious if true!
"Now, with EpiPen as the only maker of the lifesaving medicine, both doctors and patients are reporting a four to five time increase in the price of the product."
Google message title for discussion article.
This development may, just may be the biggest motivator to get the FDA moving on approving TEVA's competing product (brought to you by an ATRS injector).
Speaking of "Fueling The Fire" ----
Stories (true or not) like the following are getting people's attention on needing the availability of EpiPens practicality everywhere:
June 11, 2016 ---
Woman Dies After Kissing Boyfriend Who Ate Peanut Butter Sandwich
by Franklin Staff — June 13, 2016
The stock of Antares Pharma Incorporated registered an increase of 7.45% in short interest. ATRS’s total short interest was 8.59 million shares in June as published by FINRA. Its up 7.45% from 7.99 million shares, reported previously. With 397,400 shares average volume, it will take short sellers 22 days to cover their ATRS’s short positions. The short interest to Antares Pharma Incorporated’s float is 7.59%.
Interesting to note ------
London based Roots Analysis in their intro. did not reference Medac's Rasuvo (European backed) but did reference Antares's Otrexup.
Roots Analysis has announced the addition of “Global Autoinjectors Market, 2016-2026” report to its portfolio. The report provides a comprehensive analysis of the current state of autoinjectors market and the likely future evolution. It enumerates various autoinjector devices and combination products currently being developed/marketed and the corresponding market potential across different therapeutic areas. --MORE--
Google message title
Google title for note on Stockz News.
Analyst Jason Kolbert highlighted Anatabine Citrate past and present.
"During the study, the team found that endothelium produces and releases a defending molecule, called 5-methoxytryptophan (5-MTP), that acts to restrain inflammatory responses in the body, Kuo said.
During laboratory trials, they found the molecule increased the survival rate of sepsis-affected mice by 80 percent, he said.
The 5-MPT molecule can be acquired through the process of chemical synthesis at a small cost of several hundred Taiwan dollars, according to Kuo."
Google message subject for complete article.
Thanks for that, but where are you finding that information?
Sentiment: Strong Buy